Meta-Analysis of the Efficacy and Safety of P2Y12 Inhibitor Monotherapy After Short Course of Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

被引:2
|
作者
Elzanaty, Ahmed M. [1 ]
Nazir, Salik [2 ]
Awad, Mohammed T. [1 ]
Elsheikh, Eman [3 ]
Ahuja, Keerat Rai [4 ]
Donato, Anthony [5 ]
Eltahawy, Ehab A. [2 ]
机构
[1] Univ Toledo, Med Ctr, Dept Internal Med, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Med Ctr, Dept Cardiol, 2801 W Bancroft St, Toledo, OH 43606 USA
[3] Tama Univ Hosp, Dept Cardiol, Tanta, Egypt
[4] Cleveland Clin, Dept Cardiol, Heart & Vasc Inst, Cleveland, OH 44106 USA
[5] Tower Hlth Reading Hosp, W Reading, PA USA
关键词
Dual antiplatelet therapy; Short DAPT; P2Y(12) inhibitor monotherapy; DAPT duration; ELUTING STENT IMPLANTATION; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; ASPIRIN; TRIAL; RISK; CLOPIDOGREL; TICAGRELOR; 6-MONTH; EVENTS;
D O I
10.1016/j.carrev.2020.05.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Guidelines recommend dual antiplatelet therapy (DAPT) following drug-eluting stent (DES) placement for >= 12 months in acute coronary syndrome or 6 months in stable coronary artery disease. However, with the advent of newer-generation stents, the optimal duration of DAPT to balance bleeding and thrombotic risks has been debated. Objectives: We aimed to perform a meta-analysis of randomized controlled trials (RCT) comparing P2Y(12) mono-therapy in short-duration group (SDG) vs. standard treatment group (STG) course of DAPT in patients undergoing PCI. Methods: Electronic databases were searched for RCTs of patients undergoing percutaneous coronary intervention (PCI) with DES placement who received short (<= 3 months) vs. standard DAPT course (>= 12 months) and were followed for >= 12-months. Rates ofmajor adverse cardiovascular events (a composite of cardiovascularmortality, non-fatal myocardial infarction, and non-fatal stroke) were the primary outcome. Study-specific odds ratios (OR) and corresponding 95% confidence intervals were calculated using random-effects model. Results: A total of 20,706 patients (10,344 in the SDG and 10,362 in the STG) were analysed from four studies. There was no significant difference observed forMACE (OR= 0.95, 95% CI: 0.81-1.08, P =.92, I-2= 0%) myocardial infarction or stent thrombosis. However, lower rates ofmajor bleedingwere noted in the SDG (1.20 vs. 1.80%; OR: 0.61; 95% CI: 0.37-0.99; P =.04; I-2 = 71%) albeit with increased heterogeneity. Conclusion: A short duration of DAPT followed by P2Y(12) inhibitormonotherapy was comparable to 12 months of DAPT with respect to MACE and thrombotic events, with lower rates of major bleeding events in select group of patients undergoing PCI. More data is needed to assess efficacy in patients with complex lesions and high risk ACS population including those with STEMI presentation. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [41] Platelet P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: An Emerging Option for Antiplatelet Therapy De-escalation
    Verheugt, Freek W. A.
    Huber, Kurt
    Clemmensen, Peter
    Collet, Jean-Philippe
    Cuisset, Thomas
    Andreotti, Felicita
    THROMBOSIS AND HAEMOSTASIS, 2023, 123 (02) : 159 - 165
  • [42] Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis
    Gan, Xue-Dong
    Wei, Bao-Zhu
    Fang, Dong
    Fang, Qi
    Li, Kai-Yong
    Ding, Shi-Lan-Ying
    Peng, Song
    Wan, Jing
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (12) : 2313 - 2323
  • [43] P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
    Sotomi, Yohei
    Matsuoka, Yuki
    Hikoso, Shungo
    Nakatani, Daisaku
    Okada, Katsuki
    Dohi, Tomoharu
    Kida, Hirota
    Oeun, Bolrathanak
    Sunaga, Akihiro
    Sato, Taiki
    Kitamura, Tetsuhisa
    Sakata, Yasushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [44] P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials
    Yohei Sotomi
    Yuki Matsuoka
    Shungo Hikoso
    Daisaku Nakatani
    Katsuki Okada
    Tomoharu Dohi
    Hirota Kida
    Bolrathanak Oeun
    Akihiro Sunaga
    Taiki Sato
    Tetsuhisa Kitamura
    Yasushi Sakata
    Scientific Reports, 13
  • [45] Guided P2Y12 inhibitor therapy after percutaneous coronary intervention
    Sibbing, Dirk
    Kastrati, Adnan
    LANCET, 2021, 397 (10283): : 1423 - 1425
  • [46] Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
    Gelbenegger, Georg
    Schoergenhofer, Christian
    Jilma, Bernd
    Gager, Gloria M.
    Dizdarevic, Al Medina
    Mamas, Mamas A.
    Parapid, Biljana
    Velagapudi, Poonam
    Siller-Matula, Jolanta M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (02) : 424 - 431
  • [47] P2Y12 blocker monotherapy after percutaneous coronary intervention
    F. W. A. Verheugt
    P. Damman
    S. A. J. Damen
    J. J. Wykrzykowska
    E. C. I. Woelders
    R. -J. M. van Geuns
    Netherlands Heart Journal, 2021, 29 : 566 - 576
  • [49] P2Y12 blocker monotherapy after percutaneous coronary intervention
    Verheugt, F. W. A.
    Damman, P.
    Damen, S. A. J.
    Wykrzykowska, J. J.
    Woelders, E. C. I.
    van Geuns, R. -J. M.
    NETHERLANDS HEART JOURNAL, 2021, 29 (11) : 566 - 576
  • [50] Efficacy and Safety of Shortened Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
    Hui, Jiaojiao
    Bai, Ting
    Liang, Le
    He, Qingqing
    Tian, Nani
    Li, Xiao
    Yang, Rui
    Zhu, Lin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2022, 80 (05) : 700 - 708